---
title: "Medicus Pharma’s SkinJect Phase 2 Data Validated by KOL With 80% Response Rate"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281049436.md"
description: "Medicus Pharma’s SkinJect Phase 2 Data Validated by KOL With 80% Response Rate"
datetime: "2026-03-30T15:22:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281049436.md)
  - [en](https://longbridge.com/en/news/281049436.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281049436.md)
generator: "portal-rs"
---

# Medicus Pharma’s SkinJect Phase 2 Data Validated by KOL With 80% Response Rate

Medicus Pharma’s SkinJect Phase 2 Data Validated by KOL With 80% Response Rate

### Related Stocks

- [MDCX.US](https://longbridge.com/en/quote/MDCX.US.md)
- [MDCXW.US](https://longbridge.com/en/quote/MDCXW.US.md)

## Related News & Research

- [Medicus Pharma signs co-development, licensing deal with Pfizer for CD228V antibody-drug conjugate](https://longbridge.com/en/news/297910433.md)
- [Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update | MDCX Stock News](https://longbridge.com/en/news/295715209.md)
- [EXCLUSIVE: Medicus Pharma Launches Genomics-Guided Endometriosis Study In Abu Dhabi](https://longbridge.com/en/news/294506242.md)
- [Medicus Pharma wins FDA backing for optimized Phase 2 Teverelix study in acute urinary retention](https://longbridge.com/en/news/292898007.md)
- [EXCLUSIVE: Penny Stock Medicus Pharma Findings Support Potential In Women's Health Pipeline](https://longbridge.com/en/news/282836614.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**